cytochrome b5 type A pseudogene 4Genealiases: CYB5P4 · Psgb-5-2 · bA189G24.1
Q-omics provides the consensus-scored CYB5AP4 profile across patient tissues and cancer cell-line models. CYB5AP4 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, CYB5AP4 is differentially expressed in 1, with the highest sampling consensus in COAD. Additionally, CYB5AP4 RNA expression shows 6,540 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CESC, COAD, and STAD as cancer lineages where CYB5AP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYB5AP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYB5AP4 survival associations across molecular data types. CYB5AP4 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYB5AP4 RNA expression–survival associations across cancer types. High CYB5AP4 expression shows unfavorable associations in CESC, SKCM, READ, UCS and BLCA, but favorable associations in ESCA. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for CYB5AP4 RNA expression.
This table summarizes CYB5AP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CYB5AP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYB5AP4 shows higher tumor expression in COAD. The COAD box plot shows higher CYB5AP4 RNA expression in tumor versus normal tissue (log2 FC = +0.059, t-test p = .032).
This table shows molecular features associated with CYB5AP4 in patient tissues and cancer cell lines. In patient samples, CYB5AP4 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
